OncoMed Pharmaceuticals (OMED) News Today → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free OMED Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIonis Pharmaceuticals Stock (NASDAQ:IONS), Analyst Ratings, Price Targets, Predictionsbenzinga.com - June 8 at 11:04 AMBispecific Antibody Market Size | Statistics By 2031marketwatch.com - April 7 at 8:51 AM2023, Bispecific Antibody Market is thriving worldwide by 2029marketwatch.com - March 30 at 9:56 AM2023-2029 Cancer Stem Cell Market Size and Risks Factors Analysis | Survey Report by Absolute Reportsmarketwatch.com - February 28 at 2:13 PMForecast for 2028, Bispecific Antibody Market 2023, Global Industry Trends, Share, Size, Growth, Demandmarketwatch.com - February 27 at 5:05 PMBispecific Antibody Market : Top Key Players Data with Upcoming Opportunities and Innovationsmarketwatch.com - February 16 at 12:46 PMBispecific Antibody Market Insights-Industry changing aspects, New Technologies and Forecast to 2029marketwatch.com - February 4 at 7:57 AMBispecific Antibody Market Size [2023-2028] | Industry Share, Growth Factor, Revenue And Trends Outlook Reportmarketwatch.com - January 19 at 3:43 AMBispecific Antibody Market New Innovations and Future Expansion 2022-2028 with Top Countries Datamarketwatch.com - November 18 at 10:17 PMFallopian Tube Cancer Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightfinance.yahoo.com - November 14 at 2:40 PMImugene welcomes drug development, oncology and cell therapy expert to the teamau.investing.com - September 7 at 2:16 AMShuttle Pharmaceuticals Shares Continue to Surge, Rising 74%marketwatch.com - September 1 at 5:50 PMShuttle Pharmaceuticals Shares More Than Triple in Debutmarketwatch.com - August 31 at 4:34 PMClosing Bell: Stocks End Higher As Corporate Earnings Take Focusthestreet.com - August 16 at 8:42 PMBusiness of Pride: When social injustice calls, Nkarta answersbizjournals.com - June 10 at 1:59 AMWorldwide Bispecific Antibody Market to 2028 - Ongoing Clinical Trials Assessment by Status, Phase, and Regionfinance.yahoo.com - May 25 at 11:42 PMInsights on the Bispecific Antibody Global Market - Approved Drug Sales Forecast Till 2028finance.yahoo.com - May 24 at 9:57 PMJim Cramer's 'Mad Money' Recap: You'll Make More Money Buying Into Panicthestreet.com - April 29 at 7:03 PMAdenoid Cystic Carcinoma Pipeline is Indicative of Many Opportunities Left For Research and Development, Analyzes DelveInsightfinance.yahoo.com - March 10 at 6:03 PMUS Cancer Antibodies Market 2028uk.finance.yahoo.com - February 18 at 7:24 PMCowden Syndrome Treatment Market Trending Report 2021| Size, Share, Status and Revenue and Future Predictions to 2027marketwatch.com - October 15 at 4:04 AMKuick Research: Global Bispecific Antibody Market Forecast Trends Sales Size Insight 2028finanznachrichten.de - October 6 at 2:21 PMGlobal Bispecific Antibody Market Forecast Trends Sales Size Insight 2028prnewswire.com - October 6 at 2:21 PMAdagio Therapeutics, Inc.: Adagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of Directorsfinanznachrichten.de - July 30 at 9:05 PMAdagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of Directorsfinance.yahoo.com - July 29 at 7:33 AM Get OncoMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OMED and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… OMED Media Mentions By Week OMED Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OMED News Sentiment▼0.000.61▲Average Medical News Sentiment OMED News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OMED Articles This Week▼00▲OMED Articles Average Week Get OncoMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OMED and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LIAN News APM News DRRX News SLS News NLTX News BIOR News ACST News PMN News EFTR News SPRB News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OMED) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoMed Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.